Complete AMBAR results

Read more

AMBAR

The story of Grifols and AMBAR (Alzheimer Management by Albumin Replacement) is about commitment and innovation.

Since 2004, our rigorous scientific research has focused on finding a treatment to slow down the progression of Alzheimer's, a disabling disease that affects more than 35 million people around the world. This number could grow to as many as 82 million by 2030.

Grifols' research began with a small clinical study to investigate the potential of plasma exchange with albumin to reduce the disease's progression in patients with mild-to-moderate Alzheimer's.

Fifteen years later, this research has become a phase IIb/III clinical trial: AMBAR, a protocol in which Alzheimer's patients receive plasma-protein-replacement therapy.

The AMBAR clinical trial was carried out in 41 hospitals across the U.S. and Spain, in collaboration with some of the world's leading Alzheimer's research centers and organizations.

Grifols just presented the latest encouraging AMBAR trial results at the 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, Calif., USA. New neuroimaging data are aligned with results presented over the last year showing the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer's.

The AMBAR Clinical Research Team, led by Dr. Antonio Páez, also presented the efficacy results covering both primary and secondary endpoints at other relevant scientific conferences in the Alzheimer's field: CTAD in Barcelona, Spain, in October 2018; the International Conference on Alzheimer's & Parkinson's (AD/PD) in Lisbon, Portugal, in March 2019; and the Alzheimer's Association International Conference (AAIC) in Los Angeles, Calif., USA, in July 2019. 

Over 35
million people worldwide suffer from Alzheimer's disease

15+
years of research on Alzheimer's

150+
million invested in Alzheimer's research since 2004

Over 35
million people worldwide suffer from Alzheimer's disease

15+
years of research on Alzheimer's

150+
million invested in Alzheimer's research since 2004